MedPath

Thymopolypeptides

Generic Name
Thymopolypeptides

Overview

No overview information available.

Indication

适用于胸腺发育不全综合征、运动失调性毛细血管扩张症、慢性皮肤黏膜真菌病等免疫缺陷病。对胸腺发育不全症患儿可长期应用作替代性治疗。对全身性红斑狼疮、类风湿性关节炎等自身免疫性疾病有一定的疗效。国内猪胸腺素试用于治疗发作性口疮、麻风、重症感染、慢性肾炎等伴有细胞免疫功能低下的患者时,发现对麻风和重症感染的效果最为满意,对病毒性肝炎、恶性肿瘤、某些眼病也有一定疗效。

Associated Conditions

No associated conditions information available.

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Thymopolypeptides Injection
国药准字H20003041
化学药品
注射剂
6/16/2020
Thymopolypeptides Injection
国药准字H20044082
化学药品
注射剂
10/27/2020
Thymopolypeptides Injection
国药准字H20044545
化学药品
注射剂
9/13/2021
Thymopolypeptides Injection
国药准字H20003653
化学药品
注射剂
7/1/2020
Thymopolypeptides Injection
国药准字H20003284
化学药品
注射剂
11/22/2022
Thymopolypeptides Injection
国药准字H20044067
化学药品
注射剂
11/16/2020
Thymopolypeptides Injection
国药准字H53021765
化学药品
注射剂
9/18/2020
Thymopolypeptides Injection
国药准字H23020851
化学药品
注射剂
3/20/2021
Thymopolypeptides Injection
国药准字H20003890
化学药品
注射剂
7/27/2021
Thymopolypeptides Injection
国药准字H20003331
化学药品
注射剂
8/16/2020

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.